Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Current concepts in the diagnosis and management of poorly differentiated gastrointestinal neuroendocrine carcinomas.

Koumarianou A, Chatzellis E, Boutzios G, Tsavaris N, Kaltsas G.

Endokrynol Pol. 2013;64(1):60-72. Review.

PMID:
23450449
2.

The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas.

Strosberg JR, Coppola D, Klimstra DS, Phan AT, Kulke MH, Wiseman GA, Kvols LK; North American Neuroendocrine Tumor Society (NANETS).

Pancreas. 2010 Aug;39(6):799-800. doi: 10.1097/MPA.0b013e3181ebb56f.

3.

[Therapeutic management of poorly differentiated neuroendocrine lung tumors and neuroendocrine carcinomas of the digestive system].

Pellat A, Wislez M, Svrcek M, Hammel P, Afchain P, André T.

Bull Cancer. 2016 Oct;103(10):880-895. doi: 10.1016/j.bulcan.2016.06.006. Epub 2016 Aug 6. French.

PMID:
27507031
4.

Advances in the Diagnosis and Management of Well-Differentiated and Intermediate-Differentiated Neuroendocrine Tumors of the Lung.

Wolin EM.

Chest. 2017 May;151(5):1141-1146. doi: 10.1016/j.chest.2016.06.018. Epub 2016 Jun 29. Review.

5.

Heterogeneity of grade 3 gastroenteropancreatic neuroendocrine carcinomas: New insights and treatment implications.

Fazio N, Milione M.

Cancer Treat Rev. 2016 Nov;50:61-67. doi: 10.1016/j.ctrv.2016.08.006. Epub 2016 Aug 28. Review.

PMID:
27636009
6.

Treatment of metastatic disease in patients with neuroendocrine tumors.

Niederhuber JE, Fojo T.

Surg Oncol Clin N Am. 2006 Jul;15(3):511-33, viii. Review.

PMID:
16882495
7.

Somatostatin receptor scintigraphy versus chromogranin A assay in the management of patients with neuroendocrine tumors of different types: clinical role.

Cimitan M, Buonadonna A, Cannizzaro R, Canzonieri V, Borsatti E, Ruffo R, De Apollonia L.

Ann Oncol. 2003 Jul;14(7):1135-41.

PMID:
12853358
8.

The management of extrapulmonary poorly differentiated (high-grade) neuroendocrine carcinomas.

Smith J, Reidy-Lagunes D.

Semin Oncol. 2013 Feb;40(1):100-8. doi: 10.1053/j.seminoncol.2012.11.011. Review.

PMID:
23391117
9.

Management of neuroendocrine carcinomas of the pancreas (WHO G3): A tailored approach between proliferation and morphology.

Crippa S, Partelli S, Belfiori G, Palucci M, Muffatti F, Adamenko O, Cardinali L, Doglioni C, Zamboni G, Falconi M.

World J Gastroenterol. 2016 Dec 7;22(45):9944-9953. doi: 10.3748/wjg.v22.i45.9944. Review.

10.

Locally-advanced primary neuroendocrine carcinoma of the breast: case report and review of the literature.

Angarita FA, Rodríguez JL, Meek E, Sánchez JO, Tawil M, Torregrosa L.

World J Surg Oncol. 2013 Jun 5;11:128. doi: 10.1186/1477-7819-11-128.

11.

Neuroendocrine Cancer, Therapeutic Strategies in G3 Cancers.

Rinke A, Gress TM.

Digestion. 2017;95(2):109-114. doi: 10.1159/000454761. Epub 2017 Feb 4. Review.

PMID:
28161703
12.

Postoperative recurrence and the role of adjuvant chemotherapy in patients with pulmonary large-cell neuroendocrine carcinoma.

Iyoda A, Hiroshima K, Moriya Y, Iwadate Y, Takiguchi Y, Uno T, Nakatani Y, Yoshino I.

J Thorac Cardiovasc Surg. 2009 Aug;138(2):446-53. doi: 10.1016/j.jtcvs.2008.12.037. Epub 2009 Mar 26.

13.

Nordic guidelines 2014 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms.

Janson ET, Sorbye H, Welin S, Federspiel B, Grønbæk H, Hellman P, Ladekarl M, Langer SW, Mortensen J, Schalin-Jäntti C, Sundin A, Sundlöv A, Thiis-Evensen E, Knigge U.

Acta Oncol. 2014 Oct;53(10):1284-97. doi: 10.3109/0284186X.2014.941999. Epub 2014 Aug 20. Review.

PMID:
25140861
14.

[Poorly-differentiated neuroendocrine carcinoma of ascending colon with liver metastases successfully treated with carboplatin and etoposide].

Akiyama S, Niitani T, Narasaka T, Ohto T, Gamoh M.

Gan To Kagaku Ryoho. 2011 Jul;38(7):1209-12. Japanese.

PMID:
21772114
15.

Does the WHO 2010 classification of pancreatic neuroendocrine neoplasms accurately characterize pancreatic neuroendocrine carcinomas?

Hijioka S, Hosoda W, Mizuno N, Hara K, Imaoka H, Bhatia V, Mekky MA, Tajika M, Tanaka T, Ishihara M, Yogi T, Tsutumi H, Fujiyoshi T, Sato T, Hieda N, Yoshida T, Okuno N, Shimizu Y, Yatabe Y, Niwa Y, Yamao K.

J Gastroenterol. 2015 May;50(5):564-72. doi: 10.1007/s00535-014-0987-2. Epub 2014 Aug 21.

16.

[Poorly differentiated endocrine carcinoma of the colon].

Saint-Blancard P, Hervouet M, Chapuis O.

Rev Med Interne. 2010 Jun;31(6):e10-2. doi: 10.1016/j.revmed.2009.03.368. Epub 2010 Feb 18. French.

PMID:
20167397
17.

Large cell neuroendocrine carcinoma of the lung: a clinicopathologic study of eighty-seven cases.

Takei H, Asamura H, Maeshima A, Suzuki K, Kondo H, Niki T, Yamada T, Tsuchiya R, Matsuno Y.

J Thorac Cardiovasc Surg. 2002 Aug;124(2):285-92.

18.

Activity of a three-drug combination including cisplatin (CLOVER regimen) for poorly differentiated neuroendocrine carcinoma.

Bajetta E, Catena L, Biondani P, Pusceddu S, Valente M, Bianco N, Novelli E.

Anticancer Res. 2014 Oct;34(10):5657-60.

PMID:
25275070
19.

Systemic treatment of neuroendocrine tumors with hepatic metastases.

Demirkan BH, Eriksson B.

Turk J Gastroenterol. 2012;23(5):427-37. Review.

20.

Treatment, prognostic markers and survival in thymic neuroendocrine tumours. a study from a single tertiary referral centre.

Crona J, Björklund P, Welin S, Kozlovacki G, Oberg K, Granberg D.

Lung Cancer. 2013 Mar;79(3):289-93. doi: 10.1016/j.lungcan.2012.12.001. Epub 2013 Jan 1.

PMID:
23286964

Supplemental Content

Support Center